GlyTherix Ltd is proud to be a recipient of the first round of the Pipeline Accelerator 2020-21 scheme from Therapeutic Innovation Australia (TIA). Round 1 saw the award of $685,000 to 21 projects.
Our project “Optimisation and characterisation of Miltuximab®-DFO Bioconjugation” with participation of the National Biologics Facility Victoria Node at CSIRO was assessed and chosen by an external panel on the basis of the scientific quality and potential for development of a therapeutic product. The TIA funding assists GlyTherix to access the expertise from the CSIRO Bioconjugation team to develop novel analytical methods and conjugation chemistry to facilitate GlyTherix’s existing pipeline development.
Dr Brad Walsh, CEO of GlyTherix, said: “We’d like to thank to TIA for investing in GlyTherix project to enable and accelerate translation of our research discovery towards clinical testing.”
Dr Stuart Newman, CEO of TIA, said: “The TIA Pipeline Accelerator scheme is going from strength to strength and has steadily accumulated a cohort of over 60 supported projects. We are now starting to see the benefits from earlier voucher awards in the form of commercial outcomes and clinical trials.”
The Pipeline Accelerator voucher scheme aims to lower the financial bar for Australian translational research community to access the high-quality translational research services offered by TIA Consortium.
Discover more: https://www.therapeuticinnovation.com.au/p-accelerator2020-21-outcomes